SCHEMBL6822352

SCHEMBL6822352

COc1ccc2c(c1)CCC(Cc1c[nH]cn1)=C2c1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EBP Q15125 1/20 0.48
SIGMAR1 Q99720 1/20 0.48
ESR1 P03372 4/20 0.44
CYP19A1 P11511 2/20 0.43
CYP17A1 P05093 1/20 0.43
MIF P14174 1/20 0.41
MEN1 O00255 1/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
KMT2A Q03164 1/20 0.40
NPY5R Q15761 1/20 0.38
CYP24A1 Q07973 4/20 0.38
ACHE P22303 2/20 0.38
CYP27A1 Q02318 2/20 0.38
PPARG P37231 1/20 0.38
CYP26A1 O43174 2/20 0.37
BCHE P06276 1/20 0.37
KDM4E B2RXH2 1/20 0.37
ALDH1A1 P00352 1/20 0.37
MAPT P10636 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6825286 0.92 NPY5R (0.45) EBPSIGMAR1ESR1CYP19A1CYP17A1
SCHEMBL6822297 0.84 CYP19A1 (0.43) EBPSIGMAR1CYP19A1CYP17A1MIF
SCHEMBL6825052 0.83 CYP19A1 (0.61) CYP19A1CYP17A1MEN1NPC1RAB9A
SCHEMBL6825247 0.81 CYP19A1 (0.46) CYP19A1CYP17A1MEN1NPC1RAB9A
SCHEMBL6825253 0.80 CYP19A1 (0.44) CYP19A1CYP17A1MEN1NPC1RAB9A
SCHEMBL6825819 0.78 NPC1 (0.36) SIGMAR1CYP19A1NPC1RAB9A
SCHEMBL6822421 0.77 CYP19A1 (0.50) SIGMAR1CYP19A1CYP17A1NPY5RKDM4E
SCHEMBL7585624 0.76 ESR1 (0.52) EBPSIGMAR1ESR1MIFNPC1
SCHEMBL6825388 0.75 CYP19A1 (0.39) SIGMAR1CYP19A1CYP17A1NPY5RKDM4E
Hydrochloric Acid SCHEMBL8011767 0.75 ESR1 (0.51) EBPSIGMAR1ESR1MIFNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1028110-B1 NOVEL DIHYDRONAPHTHALENE COMPOUNDS AND PROCESS FOR PRODUCING THE SAME DAIICHI SEIYAKU CO (JP) 2004-04-14 EP claimed
EP-1028110-B1 NOVEL DIHYDRONAPHTHALENE COMPOUNDS AND PROCESS FOR PRODUCING THE SAME DAIICHI SEIYAKU CO (JP) 2004-04-14 EP disclosed
US-6559157-B2 Excellent 17 alpha - hydroxylase/C17-20-lyase and aromatase inhibiting activity, thromboxan A2 synthesis inhibiting activity, useful as preventive and/or therapeutic agents for various male and female sex hormone dependent diseases DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2003-05-06 US disclosed
US-20020032211-A1 Novel dihydronaphthalene compounds and processes of producing the same DAIICHI PHARMACEUTICALS CO., LTD. (JP) 2002-03-14 US disclosed
EP-1028110-A1 NOVEL DIHYDRONAPHTHALENE COMPOUNDS AND PROCESS FOR PRODUCING THE SAME Yukijirushi Nyugyo Kabushiki Kaisha (JP) 2000-08-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020032211-A1 Novel dihydronaphthalene compounds and processes of producing the same CYP19A1, HSD17B11, CYP17A1 EBP 1886/4885SIGMAR1 4364/4885ESR1 106/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.